Why Shares of MacroGenics Climbed Thursday
The cancer-focused biotech delivered a strong earnings report....…
3,053€
0,89%
Echtzeit-Aktienkurs MacroGenics Inc.
Bid:
Ask:
Nachrichten zur MacroGenics Inc. Aktie
MacroGenics stock climbs ~10% as FY22 revenue rises beating estimates
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
MacroGenics (MGNX) Q4 2022 Earnings Call Transcript
MGNX earnings call for the period ending December 31, 2022....…
MacroGenics GAAP EPS of -$1.95 misses by $0.07, revenue of $151.94M beats by $1.88M
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Insiderhandel: Senior VP and General Counsel verkauft Aktien von MacroGenics im Wert von 32.393$
Peters, Jeffrey Stuart - Vorstand - Tag der Transaktion: 2023-03-10...…
MacroGenics expands license agreement with Synaffix
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K MACROGENICS INC For: Mar 10
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
MacroGenics Shares Drop 12% After Thursday Move Higher
MacroGenics Shares Drop 12% After Thursday Move Higher...…
Why Shares of MacroGenics Jumped Thursday
The company made a sale worth as much as $200 million for the royalty rights for its type-1 diabetes therapy....…
MacroGenics Shares Rise 16% After Sale of Tzield Royalty Interest
MacroGenics Shares Rise 16% After Sale of Tzield Royalty Interest...…
MacroGenics unloads TZIELD royalty stake for up to $200M to a unit of DRI
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million
ROCKVILLE, MD, March 08, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing…
MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call
ROCKVILLE, MD, March 07, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing…
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD, March 02, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on…
Strength Seen in MacroGenics (MGNX): Can Its 25.7% Jump Turn into More Strength?
MacroGenics (MGNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate…
Insiderhandel: Insider kauft Aktien von MacroGenics im Wert von 2.532.600$
Biotech, Target N V. - Zehn-Prozent-Eigentümer - Tag der Transaktion: 2023-02-14...…
MacroGenics phase 1 prostate cancer asset data leads to phase 2 initiation later in 2023
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium
ROCKVILLE, MD, Feb. 13, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on…
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD, Feb. 06, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on…
Insiderhandel: Insider kauft Aktien von MacroGenics im Wert von 794.925$
Biotech, Target N V. - Zehn-Prozent-Eigentümer - Tag der Transaktion: 2023-01-19...…
MacroGenics (MGNX) Stock Sinks As Market Gains: What You Should Know
MacroGenics (MGNX) closed the most recent trading day at $5.70, moving -0.35% from the previous trading session....…
MacroGenics to Present at the 41st Annual J.P. Morgan Healthcare Conference
ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on…
MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors
ROCKVILLE, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and…